Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YB1 ADC CD47

Next Previous
Drug Profile

YB1 ADC CD47

Alternative Names: YB1-ADC-CD47

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Hong Kong
  • Developer HKND YB1 PHARMACEUTUCAL
  • Class Antibodies; Antineoplastics; Bacteria; Drug conjugates; Immunoconjugates
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Aug 2026 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
  • 11 Jul 2022 Preclinical trials in Solid tumours in China (Parenteral) before July 2022 (HKND YB1 PHARMACEUTUCAL website, July 2022)
  • 01 Jan 2021 HKND YB1 PHARMACEUTICAL establishes a strategic partnership with HKU of the University of Hong Kong and obtains the exclusive license and commercial exploitation right of all YB1 patents (HKND YB1 PHARMACEUTICAL website, July 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top